| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82cbc291d77c061ac9a216f86ec010a3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1adc63dc7c6088ae9c736e3f3bce073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e998ffc118187fe8646a2f223f3f5a1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca0c232e3530166abd203eaa163b7a16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ac72b6cf115d0dd89cb0ccbf9b50ca6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f293f62a2e81af63d8b4979cf80f8aaf |
| publicationDate |
2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012034668-A |
| titleOfInvention |
Humanized anti-EGFR antibody lysine-substituted variable region fragment and use thereof |
| abstract |
A humanized anti-EGFR antibody lysine-substituted light chain that sufficiently retains the binding activity (affinity) to a target cell and can achieve various chemical modifications in a site-specific and uniform manner. Alternatively, provision of the same heavy chain variable region fragment, or a single chain antibody composed thereof. In the humanized variable region of the light chain or heavy chain of an anti-human epidermal growth factor receptor 1 (Her1) antibody 528 comprising a specific amino acid sequence, all lysine residues or a specific site A humanized anti-EGFR antibody lysine-substituted light chain variable region fragment, wherein all lysine residues other than lysine residues are substituted with other amino acids. [Selection] Figure 4 |
| priorityDate |
2010-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |